Most Recent
Monster Energy drops challenge to Fernbrew ‘beast’ trade mark
Consumer Goods 2018-11-20 2:39 pm By Cat Fredenburgh Melbourne

Energy drink giant Monster Energy has dropped its challenge to a ruling allowing alcoholic spirits wholesaler Fernbrew to trade mark the term ‘Real Beast’ for alcoholic beverages.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Network 10 to ‘fiercely defend’ Boss trade mark case by Fairfax
Baker McKenzie 2018-11-15 1:34 pm By Miklos Bolza Sydney

Network 10 told a court Thursday it would “fiercely defend” a trade mark case brought by Fairfax Media over 10’s recent rebrand and its newly approved trade mark, 10 Boss.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Ingenuity’ needed for software-aided biz method patent, IP Australia says
Australian Government Solicitor 2018-11-09 9:18 pm By Miklos Bolza Sydney

A software-implemented business method could be patentable if programmed into a computer with “some ingenuity”, IP Australia told the Full Federal Court as a landmark appeal between rival tech companies Encompass and Infotrack wrapped up Friday.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Full Court urged to take ‘nuanced’ view of software patentability
Australian Government Solicitor 2018-11-08 8:40 pm By Miklos Bolza Sydney

Fintech company Encompass has asked the Full Federal Court to take a more “nuanced” approach to software patentability than the one currently held by IP Australia, on the first day of a high-stakes appeal over the patentability of computer-related inventions.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Otsuka defence threatened in Abilify patent case
Allens 2018-11-05 9:03 pm By Miklos Bolza Sydney

The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical’s defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Generic Health wins ‘modest’ cut to Bayer’s $25M damages over Yasmin
Chief Justice James Allsop 2018-10-31 11:59 pm By Christine Caulfield Melbourne

Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer’s blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

IP lawyers seek to intervene in software patent appeal
Appeals 2018-10-29 9:38 pm By Cat Fredenburgh Melbourne

A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Aristocrat wins discovery to probe theft of slot machine idea
Entertainment 2018-10-11 10:49 pm By Cat Fredenburgh Melbourne

Aristocrat Technologies has hit the jackpot in its bid for discovery to determine whether it has claims against rival Ainsworth for stealing its confidential information and using it to design a competing slot machine.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge puts ASIC ‘fees for no service’ case against NAB on fast-track
Competition & Consumer Protection 2018-10-08 10:56 pm By Miklos Bolza Sydney

A Federal Court judge has put ASIC’s first fees for no service case, brought against two units of National Australia Bank’s wealth management division, on an expedited timetable, saying the case was not new territory for the bank.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

QRxPharma defendants can access class members’ broker details
Class Actions 2018-09-13 11:49 pm By Miklos Bolza Sydney

The defendants in a shareholder class action over QRxPharma’s alleged failure to disclose problems with regulatory approval for its painkiller Moxduo have won access to information on class members’ financial brokers.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?